Precision Brain Stimulation Guidance for Drug-Resistant Epilepsy

Inquiry

What if clinicians could use real-time brain mapping to select better deep brain stimulation settings for patients with drug-resistant epilepsy?

Innovation

Tablet-based clinician software that uses scalp EEG biomarkers to guide deep brain stimulation programming and predict patient-specific seizure suppression settings.

Company:

Cortalis Neuro (Mayo Clinic Arizona)

Research Partner

Mayo Clinic College of Medicine and Science in Arizona

Principle Investigator

Jonathon J. Parker, MD, PhD

Research Objective:

Product Development

Cohort:

5

Visit Site

C

ortalis Neuro is developing clinician-facing software to improve deep brain stimulation programming for patients with drug-resistant epilepsy. Current DBS programming often relies on trial and error, with months between adjustments and limited biologic feedback to guide settings. Cortalis uses scalp EEG during low-frequency DBS mapping to measure evoked potentials and help clinicians understand how different stimulation patterns affect a patient’s brain. Delivered through tablet-based software that works alongside existing DBS systems and an FDA-cleared EEG headset, Cortalis aims to make DBS programming faster, more data-driven, and more personalized for seizure suppression.

No items found.

Innovator's Journey:

WearTech Ecosystem

Our network of partners can help connect project teams with resources.

WATCH more

press

WearTech: One of Arizona's newest wearable tech companies

FOX10

Wearable technology initiative receives $1.6M in funding from Arizona Commerce Authority

Phoenix Business Journal

WearTech Applied Research Center and GoX Labs Unveil Made-in-Arizona Superhuman Exoskeleton

Robotics Tomorrow

Back to projects

Thank you for subscribing!
Error!